GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (XAMS:KDS) » Definitions » Common Stock

Kiadis Pharma NV (XAMS:KDS) Common Stock : €4.03 Mil (As of Dec. 2020)


View and export this data going back to 2015. Start your Free Trial

What is Kiadis Pharma NV Common Stock?

Kiadis Pharma NV's quarterly common stock increased from Dec. 2019 (€2.96 Mil) to Jun. 2020 (€4.00 Mil) and increased from Jun. 2020 (€4.00 Mil) to Dec. 2020 (€4.03 Mil).

Kiadis Pharma NV's annual common stock increased from Dec. 2018 (€2.43 Mil) to Dec. 2019 (€2.96 Mil) and increased from Dec. 2019 (€2.96 Mil) to Dec. 2020 (€4.03 Mil).


Kiadis Pharma NV Common Stock Historical Data

The historical data trend for Kiadis Pharma NV's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV Common Stock Chart

Kiadis Pharma NV Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Common Stock
Get a 7-Day Free Trial Premium Member Only 1.40 1.73 2.43 2.96 4.03

Kiadis Pharma NV Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.43 2.96 2.96 4.00 4.03

Kiadis Pharma NV Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Kiadis Pharma NV (XAMS:KDS) Business Description

Traded in Other Exchanges
N/A
Address
Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP
Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (XAMS:KDS) Headlines

No Headlines